New Delhi: Russia’s recently approved covid-19 vaccine named Sputnik V appears to be safe without any serious adverse events and eliciting antibody response in small human clinical trials’ preliminary results, published in the Lancet Journal on Friday.Results from two early‐phase non‐randomised vaccine trials for Sputnik V in a total of 76 people found that two formulations of a two‐part vaccine have a good safety profile with no serious adverse events detected over 42 days, and induce antibody responses in all participants within 21 days.The trial results also suggest the vaccines also produce a T cell response within 28 days that provides long term immunity in the body.